Gene Therapy For Lethal Glycogen Storage Disease Wins EMA PRIME Designation
Ten products have been granted PRIME designation so far this year
Executive Summary
Investigational products from Ultragenyx and MinervaX secured a place on the European Medicines Agency’s priority medicines scheme this month.
You may also be interested in...
MinervaX Hopes To Match Pfizer In Group B Streptococcus Vaccines Race
The Danish biotech has secured more funding for a late-stage program to advance its vaccine against Group B streptococcus, which is in a race for approval with Pfizer's product.
PRIME Dry Spell Over As EMA Says Yes To Pfizer & BioCryst
This year’s first designations under the European Medicines Agency’s priority medicines scheme have gone to a maternal vaccine for an infection in newborns and a treatment for an ultra-rare bone disorder.
Outlook Turns To Marketing Strategy After Scoring EU First For Ophthalmic Bevacizumab
Outlook Therapeutics’ intravitreally injected Lytenava has won the thumbs up from the European Medicines Agency. The company is assessing both direct commercialization of the product and partnering in Europe on a country-by-country basis.